What is Athersys Inc?
Athersys Inc. is a biotechnology company dedicated to the discovery and development of therapeutic product candidates aimed at enhancing human health and longevity. The company's core focus is on its patented MultiStem® cell therapy, an adult-derived, "off-the-shelf" stem cell product. This innovative therapy is being evaluated across multiple ongoing clinical trials for various disease indications, including neurological disorders, inflammatory and immune conditions, cardiovascular diseases, and other critical care areas. Athersys has established strategic partnerships and a wide network of collaborations to accelerate the path toward commercializing its regenerative medicine product.
How much funding has Athersys Inc raised?
Athersys Inc has raised a total of $264.5M across 9 funding rounds:
Share Placement
$9M
Debt
$25M
Stock Offering
$23M
Debt
$100M
Share Placement
$7M
Share Placement
$12M
Other Financing Round
$10.4M
Share Placement (2012): $9M supported by Undisclosed
Debt (2013): $25M featuring Aspire Capital
Stock Issuance/Offering (2017): $23M backed by Undisclosed
Debt (2018): $100M with participation from Aspire Capital
Share Placement (2020): $7M led by Healios
Share Placement (2022): $12M, investors not publicly disclosed
Other Financing Round (2023): $10.4M, investors not publicly disclosed
Key Investors in Athersys Inc
Pappas Ventures
Pappas Ventures is a global investment firm focused on advancing life science discoveries and fostering innovative companies. With extensive experience, they target a wide range of human diseases and have a portfolio including successful therapies generating substantial revenue.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies. They aim to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Aspire Capital
Aspire Capital is a reliable and reasonable investor in publicly traded companies, believing in long-term, win-win relationships where their incentives are aligned with their partner companies' best interests. They are committed to being good partners, not just a source of investment.
What's next for Athersys Inc?
The recent major strategic investment in Athersys Inc. signals a pivotal phase for the company, likely focused on scaling its operations and advancing its MultiStem® cell therapy through late-stage clinical trials and toward market approval. This infusion of capital, alongside the company's total funding of $264.5M, will be instrumental in supporting its research and development initiatives, expanding manufacturing capabilities, and potentially forging new commercial partnerships. The company's strategic direction appears geared towards solidifying its position in the competitive regenerative medicine landscape and achieving its long-term vision of transforming patient care.
See full Athersys Inc company page
